Advancing high-altitude medicine: a model for the future Authors: Wenjin Sun, Xuan Zhang, Ling Chen, Lei Chen, Cheng Deng, Shizheng Wu, Fengming Luo Published: 2026 ABSTRACT AbstractWith rising global high-altitude travel, occupational exposure, and permanent habitation, the health burden of high-altitude-specific diseases and high-altitude-related diseases has become increasingly prominent, highlighting an urgent need for in-depth research and clinical solutions in high-altitude medicine. To bridge this gap, this prospective review first proposes the Hypoxia Stress-induced Multi-organ Injury (HSMI) Spectrum as a novel, unifying research paradigm—one that seeks to overcome the limitations of fragmented traditional research by integrating insights into hypoxia-driven multi-organ pathophysiology. Despite growing foundational advances, critical barriers remain: incomplete understanding of individual hypoxia susceptibility mechanisms, overreliance on subjective and non-mechanism-based diagnostic tools, and a profound translational chasm between basic research and clinical therapeutics, especially for vulnerable groups like neonates, the elderly, and females. Building on the HSMI framework, we outline a comprehensive advancement strategy that includes establishing an integrated systems-based research model leveraging multi-omics and machine learning, deciphering core hypoxia-driven molecular pathways, developing objective real-time diagnostic systems with biomarkers and portable imaging, and innovating mechanism-based precision therapeutics. Implementing this HSMI-centered model will strengthen the scientific foundation of high-altitude medicine, optimize the prevention, diagnosis, and treatment of high-altitude illnesses, and offer a scalable framework for addressing health challenges in extreme hypoxic environments worldwide.Subject terms: Experimental models of disease, Biomarkers Introduction As human activities increasingly extend into high-altitude regions, understanding the distinct health impacts of these environments has become critically important. High-altitude areas, defined as those above 2500 m,1 are home to over 80 million permanent residents and attract tens of millions of travelers annually for activities such as trekking, mountaineering, and work-related purposes.2,3 The defining environmental challenge is hypobaric hypoxia—a state of reduced oxygen availability caused by lower atmospheric pressure.4–6 This primary insult initiates a cascade of systemic physiological responses that can progress to clinical injury across multiple organ systems, encompassing both high-altitude-specific pathological alterations (such as acute mountain sickness [AMS], chronic mountain sickness [CMS], high-altitude hypertension, and high-altitude hyperuricemia) and the unique pathophysiological manifestations and incidence characteristics of common diseases (e.g., tumors, liver diseases, muscle loss, skin diseases, alopecia, and oral diseases) in high-altitude hypoxic conditions.7–13 It is precisely based on the gradual observation and in-depth understanding of these physiological adaptations and pathological injuries that High-Altitude Medicine has emerged and evolved. Since the early descriptions of AMS and the seminal physiological work in the 19th century,14–19 the field has advanced substantially: it matured through the 20th century with the characterization of life-threatening conditions like high-altitude pulmonary edema (HAPE) and high-altitude cerebral edema (HACE), the standardization of diagnostic tools such as the Lake Louise Score,20 and the progressive clarification of clinical phenotypes of other prevalent disorders—including high-altitude pulmonary hypertension (HAPH), high-altitude heart disease (HAHD), polycythemia, and hyperuricemia.7,18,21,22 This progress established a foundational understanding of major altitude illnesses.23–25 Notably, our epidemiological investigation provides important data references: a cross-sectional study of 2540 adults identified 78 high-altitude polycythemia (HAPC) cases (overall prevalence 3.07%), with prevalence increasing significantly with altitude (0.39% at 2000–2500 m, 3.36% at 2500–3300 m, and 8.06% at 4400–5300 m). Concurrently, high-altitude hyperuricemia also exhibited altitude-dependent elevation (8.52% at 2000–2500 m, 12.21% at 2500–3300 m, and 14.89% at 4400–5300 m) (Table 1). These findings confirm that hypobaric hypoxia drives progressive multi-organ impairment (e.g., hematological and renal-metabolic perturbations) with rising altitude, indicating high-altitude illnesses are interconnected manifestations of systemic hypoxic insult rather than isolated disorders. Table 1Prevalence of high-altitude polycythemia and High-altitude hyperuricemia at different altitudes on the plateauAltitudePrevalenceHigh altitude polycythemiaHigh-altitude hyperuricemiaNn%Nn%2000–2500 m103340.391033888.522500–3300 m1011343.36100712312.214400–5300 m496408.064947414.89The sample size for high-altitude hyperuricemia analysis was slightly reduced due to several hemolyzed specimens Prevalence of high-altitude polycythemia and High-altitude hyperuricemia at different altitudes on the plateau The sample size for high-altitude hyperuricemia analysis was slightly reduced due to several hemolyzed specimens Despite these foundational advances, High-Altitude Medicine is hindered by a core limitation: an overreliance on an isolated, reductionist framework that treats high-altitude illnesses as disconnected entities. This fragmented approach has stagnated deeper pathophysiological understanding and precluded transformative progress. To address this gap, we propose the hypoxia stress-induced multi-organ injury (HSMI) spectrum. The HSMI spectrum elucidates the hierarchical relationship and temporal sequence of multi-organ interactive pathology: hypobaric hypoxia first triggers universal molecular perturbations (e.g., HIF-1/2α activation, endothelial dysfunction, ROS generation) that act as upstream initiators.26 Subsequently, specific organs respond according to their structural/functional characteristics and metabolic demands. In the acute phase, core organs with high oxygen demand (lungs and brain) experience immediate, rapid cellular hypoxia and vascular barrier impairment. Concurrently, hypoxia-sensitive systems like the gastrointestinal tract undergo splanchnic hypoperfusion, leading to gut microbiota dysbiosis, mucosal barrier disruption, and the subsequent translocation of luminal endotoxins (Lipopolysaccharide, LPS) into the portal circulation. During chronic exposure, persistent systemic hypoxia stimulates HIF-2α to drive sustained excessive erythropoiesis, coupled with vascular endothelial remodeling. Concurrently, hypoxia-induced metabolic fuel rewiring activates the “gut-liver-kidney axis”.26–28 which further promotes HIF-mediated aberrant lipid metabolism, persistent systemic inflammation, and irreversible structural remodeling (e.g., pulmonary arterial hypertension, hepatic steatosis, and renal fibrosis) (Fig. 1). By centering on shared pathophysiological origins rather than isolated organ symptoms, the HSMI spectrum offers a critical shift to align the field with the biological reality of hypoxic injury. Hypoxia stress-induced multi-organ injury (hsmi) spectrum Necessity of advancing High-Altitude Medicine research High-Altitude Medicine stands at a critical juncture, defined not by a lack of foundational knowledge but by a twenty-year innovation plateau that creates growing dissonance with escalating demands of global high-altitude engagement. This stagnation spans theoretical models to clinical applications, creating an urgent need for paradigm shifts driven by convergent challenges that threaten to undermine public health security in mountainous regions worldwide. The demographic landscape has undergone a dramatic transformation, exemplified by a tripling of annual tourist arrivals in Tibet, which grew from 20 million in 2015 to over 60 million in 2024. This surge in non-acclimatized individuals has fundamentally overwhelmed the predictive and preventive capabilities of current medical frameworks. In critical regions like the Qinghai–Tibet Plateau, public health reports consistently demonstrate high-altitude illness incidence rates exceeding 30% among new arrivals,29 while rapid ascent was found with a 75% AMS rate.30 This exponential growth necessitates an urgent evolution toward comprehensive service chains covering pre-ascent risk stratification and precision medicine. Simultaneously, pathophysiological understanding requires fundamental recalibration beyond classical compartmentalized approaches. Emerging research reveals that more than 60% of HAPE patients exhibit measurable neurological symptoms,31 while CMS patients frequently demonstrate concurrent high-altitude hypertension and metabolic dysfunction.32–39 These clinical observations strongly support reinterpreting these conditions as manifestations of a unified HSMI spectrum. This reconceptualization proves essential for identifying core signaling hubs—particularly HIF-1/2α-mediated pathways that simultaneously regulate erythropoiesis, pulmonary vascular response, cerebral angiogenesis, intestinal barrier integrity, and hepatic metabolic switching—that underlie systemic decompensation across apparently distinct clinical presentations.40–48 The most formidable barrier remains intrinsic limitations in the research-to-clinical pipeline. The translational gap persists despite the identification of multiple potential biomarkers in the past decade.17,49–51 Breaking this cycle demands the establishment of a novel research paradigm centered on the HSMI spectrum—one that integrates multi-omics data, real-world monitoring, and computational modeling to construct a dynamic, systems-level understanding of human hypoxia response. Challenges in current High-Altitude Medicine Fragmented understanding of the disease spectrum The prevailing reductionist approach to high-altitude pathology represents a fundamental impediment to progress. Conditions such as HAPE, HACE, HAPH, high-altitude hypertension, polycythemia, and high-altitude hyperuricemia continue to be studied as isolated entities despite mounting evidence of their interconnected pathophysiology. Furthermore, common diseases exhibiting unique pathophysiological trajectories under hypoxia—such as high-altitude-associated metabolic liver diseases, intestinal barrier dysfunction, and distinct tumorigenesis patterns—are largely neglected by classical frameworks. The core pathological trigger—hypobaric hypoxia—initiates simultaneous systemic processes: shared molecular mechanisms including endothelial permeability defects, systemic inflammatory activation, and global metabolic dysregulation.5,52–54 Current classification systems fail to capture the hierarchical relationship and temporal continuity of these processes. Emerging evidence points to an integrated physiological rewiring cascade: acute systemic hypoxia immediately triggers fuel redistribution and vascular barrier compromise in high-demand organs (lungs, brain). Concurrently, splanchnic hypoperfusion impairs the highly sensitive intestinal mucosal barrier. This leads to increased intestinal permeability and the translocation of luminal bacteria/dysbiosis. Consequently, a progressive “gut-liver-kidney axis” of injury is established. Under chronic exposure, this sequence drives macrophage activation, aberrant lipid metabolism, and irreversible extracellular matrix deposition, culminating in structural pathologies like hepatic steatosis, renal interstitial fibrosis, and sustained.28,40,55,56 By ignoring this multi-organ interactive sequence, the traditional organ-siloed approach severely limits our ability to recognize mixed clinical phenotypes and develop comprehensive protective strategies. Unelucidated mechanisms of individual susceptibility The pronounced heterogeneity in individual responses to high-altitude exposure presents one of the field’s most persistent challenges. While genomic studies have identified specific genetic variants—for instance, the high-altitude adaptation genes endothelial PAS domain protein 1 (EPAS1) and Egl-9 family hypoxia inducible factor 1 (EGLN1) in Tibetans, and more recently, nuclear factor kappa B subunit 1(NFKB1) haplotypes associated with protective effects against hypoxic stress in the Andean Aymara population57—these collectively explain only approximately 30% of susceptibility variance in lowland populations.58–61 This limited explanatory power highlights a critical gap: current research remains focused on isolated genetic markers rather than integrated systemic determinants of hypoxic response. Crucially, the prevalence and manifestations of high-altitude pathologies vary significantly across different geographical regions, driven by convergent evolution and distinct evolutionary histories. For instance, populations residing in the Andes, the Tibetan Plateau, and the Ethiopian highlands exhibit markedly different physiological adaptations, resulting in varying susceptibilities to CMS and distinct hematological profiles.62 Current diagnostic and predictive models lack the flexibility to account for this evolutionary diversity. Additionally, individual susceptibility is highly influenced by demographic and physiological variations that remain under-researched. There are significant gender differences in physiological responses to hypoxia, manifesting in distinct hypoxic ventilatory responses and vascular reactivities,63,64 yet sex-specific preventive guidelines are absent. Similarly, the specific vulnerability of neonates facing profound cardiopulmonary transitional challenges at high altitudes,65,66 as well as the altered physiological reserves of the elderly,63 constitute a critical blind spot in modern high-altitude medical research. Limitations in current diagnostic approaches Contemporary diagnostic frameworks for high-altitude illnesses exhibit significant limitations that compromise clinical effectiveness, primarily due to their reliance on symptomatic over mechanism-based parameters. The widely utilized Lake Louise Score (LLS) for AMS relies heavily on subjective self-reporting, failing to integrate objective biomarkers tied to the systemic HSMI spectrum. This diagnostic inadequacy extends across the entire spectrum. For high-altitude hypertension, there is a lack of altitude-adapted blood pressure thresholds and real-time vascular function monitoring tools. For CMS, standardized multidimensional diagnostic criteria integrating hematological, vascular, and neurological indicators remain controversial. Furthermore, current clinical practices miss crucial early-stage pathological shifts. The lack of reliable point-of-care (POC) testing for established upstream molecular cascades—such as real-time surrogate markers for endothelial dysfunction or systemic oxidative stress—prevents clinicians from identifying pre-symptomatic multi-organ perturbations in remote environments. The absence of integration with advanced molecular screening and portable imaging (e.g., bedside ultrasound for subclinical edema or vascular resistance) hinders proactive risk stratification. Lagging innovation and clinical translation in therapeutics A profound translational chasm persists between basic pathophysiological discoveries and applied clinical therapeutics. While our understanding of hypoxia has deepened at the molecular level, the pharmacological arsenal remains essentially frozen in time. Current first-line interventions are overwhelmingly limited to decades-old, non-targeted medications (e.g., acetazolamide, dexamethasone, and basic vasodilators), addressing downstream symptoms rather than upstream causes. There is a striking absence of tailored therapeutics designed for the unique metabolic and structural challenges of high-altitude exposure. For example, no approved therapies specifically target the HIF signaling pathway to modulate inappropriate erythropoiesis or prevent pulmonary vascular remodeling. Interventions to reverse long-term chronic organ damage—such as hypoxia-driven renal fibrosis or high-altitude hyperuricemia resulting from metabolic shifts—are entirely lacking. This innovation gap, where merely a handful of novel entities have entered clinical trials for high-altitude diseases compared to hundreds in standard cardiovascular medicine,67,68 is driven by structural barriers encompassing inadequate funding, complex regulatory hurdles, and a disconnect between molecular research and clinical application. Future directions for advancing High-Altitude Medicine Shifting to an integrated, systems-based conceptual paradigm To overcome the fragmented understanding of the high-altitude disease spectrum, the foundational step is a paradigm shift from the traditional organ-siloed approach to the hypoxia stress-induced multi-organ injury (HSMI) framework. Crucially, future research must explicitly differentiate between physiological adaptation (successfully acclimatized highlanders) and pathophysiological maladaptation (diseased sojourners or uncompensated residents). The HSMI framework conceptually maps this maladaptive trajectory by recognizing acute injuries (e.g., rapid vascular barrier failure in the lungs and brain, splanchnic hypoperfusion) and chronic remodeling (e.g., sustained pulmonary vascular remodeling, hepatic steatosis, renal interstitial fibrosis) not as distinct diseases, but as a continuous, temporally defined multi-organ cascade. Adopting this integrated perspective allows researchers to investigate the hierarchical sequence of injury—such as how the “gut-liver-kidney axis” responds to systemic metabolic fuel rewiring—thereby establishing a comprehensive biological reality of hypoxic stress that accounts for mixed clinical phenotypes (Table 2). Table 2Conceptual and methodological shift: from traditional High-Altitude Medicine to the HSMI frameworkParameterTraditional High-Altitude MedicineProposed HSMI frameworkCore conceptOrgan-siloed, isolated pathological events (e.g., AMS, HAPE, HACE) are perceived as discrete diseases.Interconnected multi-organ systemic injury driven by shared upstream mechanisms (e.g., HIF dysregulation, ROS).Pathological trajectoryFocus primarily on acute, life-threatening cardiopulmonary and cerebral events.Dynamic continuum: acute barrier dysfunction/fuel rewiring progressing sequentially to chronic fibrotic/structural organ remodeling.Target organ focusConfined predominantly to the lungs and brain.Systemic network encompassing lung/brain but explicitly integrating the Gut-Liver-Kidney axis and immune-metabolic shifts.Diagnostic toolsSubjective scoring (e.g., LLS), basic portable oximetry, and reactive diagnosis upon symptom onset.Objective multi-omics biomarkers, AI-powered predictive modeling, and multimodal point-of-care (POC) devices for proactive screening.Individual susceptibilityUnder-recognized; generalized “one-size-fits-all” preventive guidelines.Precision stratification accounting for divergent evolutionary backgrounds (e.g., Tibetan vs. Andean), age (neonates to elderly), and gender.Therapeutic strategyBroad, non-targeted drugs (e.g., acetazolamide, steroids); primarily symptom relief.Mechanism-based molecular targeting (e.g., specific HIF modulators, gut epithelial protectors); disease modification and reversal of remodeling. Conceptual and methodological shift: from traditional High-Altitude Medicine to the HSMI framework Decoding individual susceptibility through multi-omics and machine learning Addressing the unelucidated mechanisms of individual susceptibility requires moving beyond single-gene association studies. Future investigations must deploy comprehensive multi-omics technologies—integrating genomics, transcriptomics, metabolomics, and microbiome profiling—coupled with advanced machine learning (AI) algorithms.69–72 This computational approach can effectively map the divergent-convergent evolution patterns observed across different high-altitude regions (such as the distinct physiological adaptations between Andean, Tibetan, and Ethiopian highlanders) and integrate these evolutionary histories into predictive models. Furthermore, precision medicine in high-altitude environments must explicitly investigate demographic vulnerabilities that have historically been neglected. Specifically, future frameworks must incorporate gender differences (accounting for hormonal influences on hypoxic ventilatory responses and vascular reactivity) and age-specific physiological reserves. Establishing targeted guidelines for highly vulnerable populations, particularly neonates facing severe cardiopulmonary transitional challenges at high altitudes, will be a critical priority in decoding holistic individual susceptibility. Revolutionizing diagnostic frameworks with objective, real-time technologies To transcend the limitations of current diagnostic approaches that rely heavily on subjective symptom reporting (e.g., the LLS), the field must adopt objective, mechanism-based diagnostic criteria. Diagnostic innovation should focus on developing deployable POC testing technologies capable of quantifying early upstream biomarkers of the HSMI spectrum—such as markers of endothelial dysfunction, systemic inflammation, and intestinal barrier compromise (e.g., circulating endotoxin levels, Interleukin‑6 concentration, endothelin-1[ET-1] levels)—in remote high-altitude settings. Simultaneously, the integration of portable, multimodal imaging technologies (such as bedside ultrasound for detecting subclinical pulmonary edema, optic nerve sheath diameter for elevated intracranial pressure, and hepatic/renal vascular resistance assessments) with wearable continuous physiological monitors is essential. By feeding real-time physiological data into AI-driven diagnostic algorithms, clinicians can transition from reactive symptom management to proactive risk stratification, detecting pre-symptomatic multi-organ perturbations before severe clinical deterioration occurs. Accelerating therapeutic translation and establishing feasible collaborative networks To overcome lagging innovation in therapeutics, pharmacological research must pivot toward mechanism-based interventions targeting the shared upstream pathways of the HSMI spectrum. Rather than relying on non-specific, decades-old medications, the development pipeline should prioritize precise molecular modulators. Promising avenues include targeted HIF-1/2α stabilization regulators to balance erythropoiesis and prevent pulmonary vascular remodeling, gut mucosal protectors to halt that drives secondary liver/kidney injury, and advanced antioxidant therapies. Crucially, these therapeutics must aim not only to mitigate acute barrier dysfunction but also to reverse or attenuate chronic structural remodeling (e.g., steatosis and fibrosis) induced by prolonged hypoxic exposure. To ensure these theoretical advancements translate into clinical reality, establishing highly feasible, national-level collaborative networks is paramount. While global harmonization may face geopolitical and logistical hurdles, establishing domestic multi-center research platforms, national high-altitude biobanks, and centralized population health registries in countries with significant high-altitude territories is highly achievable. These synchronized networks will provide the robust, large-scale clinical data necessary to validate novel biomarkers, train machine learning models, and conduct specialized clinical trials for precision therapeutics, thereby bridging the long-standing gap between basic altitude science and clinical application (Fig. 2). Future directions for advancing high-altitude medicine Conclusion As the global population engaging with high-altitude environments continues to expand rapidly, the limitations of traditional, compartmentalized approaches to high-altitude medicine have become clinically untenable. The introduction of the Hypoxia Stress-induced Multi-organ Injury (HSMI) spectrum signifies a mandatory conceptual evolution—shifting our understanding from isolated, organ-specific anomalies to an integrated continuum of systemic maladaptive responses. By embracing a framework that captures the temporal progression from acute vascular barrier failure to chronic multi-organ remodeling, and by rigorously differentiating physiological adaptation from maladaptation, we can realign medical research with biological reality. Supported by the integration of multi-omics technologies, AI-driven predictive modeling, and an acute awareness of geographic, ethnic, gender, and age-related variations, this paradigm shift will enable the transition from subjective, reactive care to objective, precision medicine. Ultimately, executing this vision through feasible national collaborative networks and mechanism-based therapeutic innovations will provide a vital roadmap to ensure the sustained health, safety, and performance of tens of millions of individuals living in and ascending to the world’s most challenging hypoxic environments. Acknowledgements This study was supported by grant 2025ZD0551800 from the Noncommunicable Chronic Diseases-National Science and Technology Major Project, grant XZ202501ZY0120 from the Science and Technology Project of Xizang Autonomous Region, and grant GYYX24018 from the 1.3.5 Project of the Center for High Altitude Medicine, West China Hospital, Sichuan University. Author contributions F.L. and W.S. developed the concept and wrote the paper; X.Z., L.C., L.C., C.D., and S.W. discussed, edited, and contributed to the writing. All schematics were drawn by W.S. All authors have read and approved the article. Competing interests Authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References